Guggenheim last night initiated coverage of Corbus Pharmaceuticals (CRBP) with a Buy rating and $45 price target The company’s lead asset CRB-701 is in development for second-line head and neck squamous cell carcinoma and cervical cancer, the analyst tells investors in a research note. The firm believes Corbus has a viable development path for both of its target indications, with a “particularly compelling opportunity” in a subset of head and neck squamous cell carcinoma arising from the oropharynx.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Initiated at Buy on CRB-701 Head and Neck Cancer Opportunity, Undervalued Pipeline, and $45 Price Target
- Corbus Pharmaceuticals initiated with a Buy at Guggenheim
- Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections
- Corbus Advances CANYON-1 Phase 1b Obesity Trial Milestone
- Corbus Pharmaceuticals announces last person enrolled in CANYON-1 trial